Conduct of Development. Gen-Probe, and Chiron in the event it undertakes or is assigned by the Supervisory Board any responsibilities in connection with the Development Program for each such Initial Blood Screening Assay, shall conduct their respective obligations under the Development Program for each Initial Blood Screening Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Gen-Probe and Chiron each shall proceed diligently with their respective obligations under each such Development Program and shall use their respective Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Gen-Probe and Chiron each shall allocate sufficient personnel, equipment, facilities and other resources to each such Development Program to carry out their respective obligations and to accomplish the objectives thereof.
Conduct of Development. During the term of this Agreement, DURA shall use commercially reasonable efforts to (a) conduct the Development on behalf of Xxxxxx Corp. II in a prudent and skillful manner in accordance, in all material respects, with the annual workplan and budget then in effect and applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect and (b) diligently execute such annual workplan and budget and report to Xxxxxx Corp. II any significant deviations therefrom in a timely manner. Xxxxxx Corp. II hereby appoints DURA its exclusive agent, for the term of this Agreement, with the sole power and authority to file and prosecute all necessary regulatory applications and permits in DURA's name required to obtain FDA Approval and other regulatory approvals for the Xxxxxx Products. DURA shall, at Xxxxxx Corp. II's expense as described below, furnish all labor, supervision, services, supplies and materials necessary to perform the Development in accordance with the annual workplan and budget then in effect. In addition to its undertakings pursuant to the Technology Agreement, DURA agrees to use commercially reasonable efforts, on behalf of itself, DDSI and Xxxxxx Corp., to attempt to obtain and to sublicense to Xxxxxx Corp. II subject to the terms and conditions of the Technology Agreement, on behalf of and at the expense of Xxxxxx Corp. II but in accordance with Section 2.4 of the Technology Agreement, any patent or technology license or sublicense from any Person, including DURA, DDSI or Xxxxxx Corp., that DURA reasonably determines to be necessary or useful to enable DURA to conduct the Development under this Agreement.
Conduct of Development. Ambit has conducted, or has caused its contractors and consultants to conduct, any and all preclinical and clinical studies related to the CONFIDENTIAL Compounds and Licensed Products in accordance with good laboratory and clinical practice as and where appropriate, and Applicable Law.
Conduct of Development. Gen-Probe shall conduct its obligations under the Development Program for each Initial Clinical Diagnostic Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Gen-Probe shall proceed diligently with its respective obligations under each such Development Program and shall use its Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Gen-Probe shall allocate sufficient personnel, equipment, facilities and other resources to each such Development Program to carry out its obligations and to accomplish the objectives thereof.
Conduct of Development. AND COMMERCIALIZATION OF PRODUCT
Conduct of Development. During the term of this Agreement, CVBT shall use commercially reasonable efforts to (a) conduct the Development on behalf of CDCP in a prudent and skillful manner in accordance, in all material respects, with the work plan then in effect and applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect and (b) diligently execute such work plan and report to CDCP any significant deviations therefrom in a timely manner. CDCP hereby appoints CVBT its exclusive agent, for the term of this Agreement, with the sole power and authority to file and prosecute all necessary regulatory applications and permits in CVBT’s name required to obtain FDA and other regulatory approvals for CVBT’s Development efforts. Without limiting the generality of the foregoing sentence, absent specific requirements of the FDA to the contrary, CVBT is authorized by CDCP to conduct FDA trials in CVBT’s name. Using the Available Funds provided by CDCP, CVBT shall furnish all labor, supervision, services, supplies and materials necessary to perform the Development in accordance with the work plan then in effect. In addition, CVBT agrees to use commercially reasonable efforts, on behalf of itself and CDCP, to attempt to obtain and to sublicense any patent or technology license or sublicense from any Person, including CVBT, that CVBT reasonably determines to be necessary or useful to enable CVBT to conduct the Development under this Agreement.
Conduct of Development. 5.2.1 ABX shall perform its obligations under the Development Program for each Candidate Drug through Phase II Completion for such Candidate Drug as set forth in the applicable Development Program Work Plan pursuant to a mutually acceptable contract research services agreement (the “Contract Services Agreement”). The Contract Services Agreement shall include standard contract research services provisions, which the Parties shall negotiate in good faith and on commercially reasonable terms within [Confidential treatment requested] after the Effective Date (or such longer period as the Parties may mutually agree).
5.2.2 ABX and AZ shall conduct their respective obligations under such Development Program in accordance with this Article 5, the Contract Services Agreement and the applicable Development Program Work Plan and Program Budget, and shall use Commercially Reasonable Efforts to accomplish the objectives thereof in accordance with the timelines set forth therein. Each Party shall provide the personnel, materials, equipment and other resources required to conduct its obligations under each Development Program. Each Party shall perform its obligations under each Development Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of Applicable Law and good clinical practices. ABX and its Affiliates shall perform all of ABX’s responsibilities under the Development Programs and shall not enter into any subcontract with a Third Party to perform any such responsibilities except as expressly permitted in the applicable Development Program Work Plan or as otherwise agreed to by the Parties, provided that in any case any such permitted subcontractor shall be reasonably acceptable to AZ. Notwithstanding the foregoing, AZ shall have the right, in its sole discretion, to enter into any subcontract with a Third Party to perform any of its responsibilities under a Development Program.
Conduct of Development. Biosite and Merck each shall conduct the Development Program in good scientific manner, and in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices to attempt to achieve its objectives efficiently and expeditiously. Biosite and Merck each shall proceed diligently with the work set out in the Development Program by using their respective good faith efforts to provide, among others, the following resources:
(a) allocation of sufficient time, effort, equipment and facilities to the Development Program to carry out its obligations under the Development Program and to accomplish the objectives thereof; and
(b) use of personnel with sufficient skills and experience as are required to carry out its obligations under the Development Program and to accomplish the objectives thereof.
Conduct of Development. Chiron, and Gen-Probe (if applicable), shall conduct their respective obligations under the Development Program for each such Exclusive Future Clinical Diagnostic Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Chiron, and Gen-Probe (if applicable), each shall proceed diligently with their respective obligations under each such Development Program and shall use their respective Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Chiron shall have the right to discontinue development of any Exclusive Future Clinical Diagnostic Assay being developed by Chiron under this Section 4.2.2 at any time, in its sole discretion. Gen-Probe and Chiron each shall allocate sufficient personnel, equipment, facilities and other resources to each such Development Program to carry out their obligations and to accomplish the objectives thereof.
Conduct of Development. Gen-Probe and Chiron each shall conduct its development of each Nonexclusive Future Clinical Diagnostic Assay which it selects for development under Section 4.3.1 above in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Subject to Section 4.3.1(b), each party shall proceed diligently with its obligations under each such Development Program and shall use its Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously.
